18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Leishmanicidal and immunomodulatory properties of Brazilian green propolis extract (EPP-AF ®) and a gel formulation in a pre-clinical model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Leishmaniasis is a widespread group of neglected vector-borne tropical diseases that possess serious therapeutic limitations. Propolis has been extensively used in traditional medical applications due to its range of biological effects, including activity against infectious agents. Here we evaluated the leishmanicidal and immunomodulatory properties of Brazilian green propolis extract (EPP-AF ®) and a gel formulation incorporating EPP-AF ®, in both in vitro and in vivo models of Leishmania amazonensis infection. Propolis extract, obtained from a standardized blend following hydroalcoholic extraction, showed the characteristic fingerprint of Brazilian green propolis as confirmed by HPLC/DAD. A carbopol 940 gel formulation was obtained containing propolis glycolic extract at 3.6% w/w. The release profile, assessed using the Franz diffusion cell protocol, demonstrated a gradual and prolonged release of p-coumaric acid and artepillin C from the carbomer gel matrix. Quantification of p-coumaric acid and artepillin C in the gel formulation over time revealed that p-coumaric acid followed the Higuchi model, dependent on the disintegration of the pharmaceutical preparation, while artepillin C followed a zero-order profile with sustained release. In vitro analysis revealed the ability of EPP-AF ® to reduce the infection index of infected macrophages ( p < 0.05), while also modulating the production of inflammatory biomarkers. Decreases in nitric oxide and prostaglandin E 2 levels were observed ( p < 0.01), suggesting low iNOS and COX-2 activity. Furthermore, EPP-AF ® treatment was found to induce heme oxygenase-1 antioxidant enzyme expression in both uninfected and L. amazonensis-infected cells, as well as inhibit IL-1β production in infected cells ( p < 0.01). ERK-1/2 phosphorylation was positively correlated with TNF-α production ( p < 0.05), yet no impact on parasite load was detected. In vivo analysis indicated the effectiveness of topical treatment with EPP-AF ® gel alone ( p < 0.05 and p < 0.01), or in combination with pentavalent antimony ( p < 0.05 and p < 0.001), in the reduction of lesion size in the ears of L. amazonensis-infected BALB/c mice after seven or 3 weeks of treatment, respectively. Taken together, the present results reinforce the leishmanicidal and immunomodulatory effects of Brazilian green propolis, and demonstrate promising potential for the EPP-AF ® propolis gel formulation as a candidate for adjuvant therapy in the treatment of Cutaneous Leishmaniasis.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Botanical origin and chemical composition of Brazilian propolis.

          Brazilian propolis has been classified into 12 groups based on physicochemical characteristics: five in the southern Brazil group (group 3), one in the southeastern Brazil group (group 12), and six in the northeastern Brazil group (group 6). The plant origins of these groups were investigated using reversed-phase high-performance thin-layer chromatography (RPHPTLC), reversed-phase high-performance liquid chromatography (RPHPLC), and gas chromatography-mass spectrometry (GC-MS). It was concluded that the origins of propolis group 3, group 6, and group 12 are resins of the poplar tree, Hyptis divaricata, and Baccharis dracunculifolia, respectively.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Brazilian Red Propolis—Chemical Composition and Botanical Origin

            Propolis contains resinous substances collected by honey bees from various plant sources and has been used as a traditional folk medicine since ca 300 BC. Nowadays, the use of evidence-based complementary and alternative medicine (CAM) is increasing rapidly and so is the use of propolis in order to treat or support the treatment of various diseases. Much attention has been focused on propolis from Populus sp. (Salicaceae) and Baccharis dracunculifolia (Asteracea), but scientific information about the numerous other types of propolis is still sparse. We gathered six samples of red propolis in five states of Northeastern Brazil. The beehives were located near woody perennial shrubs along the sea and river shores. The bees were observed to collect red resinous exudates on Dalbergia ecastophyllum (L) Taub. (Leguminosae) to make propolis. The flavonoids of propolis and red resinous exudates were investigated using reversed-phase high-performance liquid chromatography and reversed-phase high-performance thin-layer chromatography. We conclude that the botanical origin of the reddish propolis is D. ecastophyllum. In areas where this source (D. ecastophyllum) was scarce or missing, bees were collecting resinous material from other plants. Propolis, which contained the chemical constituents from the main botanical origin, showed higher antimicrobial activity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

              Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                09 February 2023
                2023
                : 14
                : 1013376
                Affiliations
                [1] 1 Laboratory of Inflammation and Biomarkers , Gonçalo Moniz Institute , Oswaldo Cruz Foundation , Salvador, Bahia, Brazil
                [2] 2 Faculty of Medicine of Bahia , Federal University of Bahia (UFBA) , Salvador, Bahia, Brazil
                [3] 3 Laboratory of Research , Development and Innovation , Apis Flora Industrial e Comercial Ltda , Ribeirão Preto, São Paulo, Brazil
                [4] 4 Federal University of Western of Bahia (UFOB) , Barreiras, Bahia, Brazil
                Author notes

                Edited by: Dâmaris Silveira, University of Brasilia, Brazil

                Reviewed by: Fernando Almeida-Souza, State University of Maranhão, Brazil

                Beatriz Simonsen Stolf, University of São Paulo, Brazil

                *Correspondence: Andresa A. Berretta, andresa.berretta@ 123456apisflora.com.br ; Valéria M. Borges, vborges@ 123456bahia.fiocruz.br

                This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

                Article
                1013376
                10.3389/fphar.2023.1013376
                9949379
                36843932
                3b3299cb-38d0-4ffa-b117-c5a9dce8c3a5
                Copyright © 2023 Rebouças-Silva, Amorim, Jesus-Santos, de Lima, Lima, Berretta and Borges.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 06 August 2022
                : 30 January 2023
                Funding
                This study was supported in part by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)—Financing Code 001. VB is senior investigator from CNPq. JS holds a fellowship from CAPES.
                Categories
                Pharmacology
                Original Research

                Pharmacology & Pharmaceutical medicine
                leishmaniasis,propolis,neglected disease,natural products,l. amazonensis

                Comments

                Comment on this article